Skip to content

Cerebrospinal fluid p62/SQSTM1 is associated with tau pathology, brain structural alterations, and cognitive impairment in adults without dementia.

Oct 2026 · Journal of Alzheimer's Disease · pp. 13872877261502791 · 0 citations · 66 references
Medicine

TL;DR

Higher p62/SQSTM1 levels were associated with tau pathology and an elevated risk of AD, and Tau-related pathological changes and brain structural alterations might be involved in the relationship between the p62/SQSTM1-related autophagy processes and cognition.

Abstract

BackgroundThe involvement of cerebrospinal fluid (CSF) Sequestosome-1 (SQSTM1, commonly known as p62), an autophagy-related scaffold protein, in Alzheimer's disease (AD) pathogenesis is not well established in human populations.ObjectiveTo investigate the associations of baseline CSF p62/SQSTM1 levels with cognitive function, AD biomarkers, brain structure, and incident dementia in non-demented individuals.MethodsWe included 557 dementia-free participants from the Alzheimer's Disease Neuroimaging Initiative cohort. Multivariate regression and interaction analyses examined associations of CSF p62/SQSTM1 with cognition, AD biomarkers, and brain volumes and their modification by age, sex, APOE genotype, and diagnostic status. Kaplan-Meier and Cox analyses assessed dementia-free survival and incident dementia risk. Mediation analysis tested whether AD pathology and brain structure mediated the association between p62/SQSTM1 and cognition.ResultsElevated CSF p62/SQSTM1 levels correlated with poorer cognition, heightened tau pathology, increased sTREM2 and PGRN levels, and decreased whole-brain and fusiform gyrus volumes. Age modified p62/SQSTM1 associations with cognition and whole-brain volume. Subgroup analyses revealed that significant associations between p62/SQSTM1 and cognitive function (MMSE, MEM) were primarily observed in the middle-aged group. Longitudinal analyses further showed that participants in the highest quartile (Q4) exhibited an increased risk compared to the lowest (Q1) (HR = 1.78, 95% CI 1.16-2.73). Mediation analysis indicated that tau pathology and reduced brain volumes mediated the association between p62/SQSTM1 and cognition.ConclusionsHigher p62/SQSTM1 levels were associated with tau pathology and an elevated risk of AD. Tau-related pathological changes and brain structural alterations might be involved in the relationship between the p62/SQSTM1-related autophagy processes and cognition.

View source

Similar papers

Sep 2026

CSF neuroinflammatory biomarkers are associated with amyloid-β42/40, tau pathology, and cognitive impairment across the Alzheimer’s disease spectrum

Higher CSF neuroinflammatory biomarkers may be linked to AD pathology and cognitive impairment; however, given the observational design, causality cannot be established, and longitudinal mechanistic studies are needed to validate these findings.

Mubarak Alruwaili, A. Turkistani, S. Shilbayeh et al. · 0 citations
Open access Oct 2026

Associations between neuropsychiatric symptoms and cerebrospinal fluid amyloid pathology, and convergent proteomic signatures in Alzheimer’s disease

Neuropsychiatric symptoms (NPSs) are highly prevalent in Alzheimer’s disease (AD) and may accelerate cognitive decline, but the molecular mechanisms linking NPSs to AD pathology remain unclear. In this cross–sectional study, we analyzed 713 Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants wi...

Ya-Yu Wang, Huai-Yuan Zhu, Wei Miao et al. · 0 citations
Open access Nov 2026

Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival

Abstract Dementia with Lewy bodies (DLB) is a common neurodegenerative dementia that remains difficult to distinguish clinically from Alzheimer's disease (AD) and related disorders because of overlapping clinical features and frequent mixed pathology. Because alpha-synuclein pathology is associated with central and per...

Ariana N. Pritha, P. Swann, M. Malpetti et al. · 0 citations
Open access Oct 2026

Cerebrospinal fluid neurofilament heavy protein levels associated with domain-specific cognitive decline in Alzheimer’s disease

Background Neurofilament proteins are fluid biomarkers of neuroaxonal damage in various neurological diseases. However, it remains to be elucidated whether CSF neurofilament heavy (NfH) protein levels correlate with cognitive decline and progression in Alzheimer’s disease (AD). Methods This study included 165 cognitive...

Jian-Jing Zhang, Xi-Wu Wang, Ling-Kai Yang et al. · 0 citations
Open access Oct 2026

Cerebrospinal fluid amyloid and neurodegeneration biomarkers in the diagnosis and prognosis of amyotrophic lateral sclerosis: a multicohort observational study.

BACKGROUND Neurofilament light chain (NfL) is an established biomarker for amyotrophic lateral sclerosis (ALS). However, it remains unclear whether biomarkers reflecting amyloid-β metabolism (Aβ), tau (phosphorylated tau, pTau), and astrogliosis (glial fibrillary acidic protein, GFAP) can complement NfL in clinical app...

Kazuki Obara, S. Janelidze, Daisuke Ito et al. · 1 citation
Open access Oct 2026

Amyloid, p‐tau, neurofilament light, and α‐synuclein cerebrospinal fluid biomarkers across Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease

Amyloid and tau positivity in DLB were associated with worse global cognitive outcomes, but not with motor performance, and NfL levels were elevated across diseases, and total α‐synuclein levels were associated with tau positivity.

Marianna Rizzo, C. Teunissen, H. Zetterberg et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.